Any current/future new fundraising through debt or equity?

No specific details on any current or immediate fundraising through debt or equity were disclosed in the discussion. The company mentioned plans for capex related to expansion (e.g., Boisar and Tarapur projects, and IBC project) but indicated that announcements on the specifics, including financing, will be made in due course, particularly by Q2. Management emphasized phased capex and cautious scaling to protect margins and maintain ROCE but did not elaborate on the mode of funding. Overall, while growth and expansion plans imply potential future fundraising needs, there is no explicit mention

Any current/future capex/capital investment/strategic investment?

Mitsu Chem Plast Limited has ongoing and planned capital expenditure (capex) linked to capacity expansion, particularly at Boisar and Tarapur facilities. The company has recently started Unit 4 and is expanding packaging lines and IBC production capacity. Additional capex will be required to achieve the INR 1,000 crores revenue target by FY'28/FY'29. Specific capex amounts and detailed project updates are to be announced progressively, with a significant project (IBC) details expected by Q2. The company follows phased capex plans aligned with operational readiness and market demand. Emphasis o

Future growth expectations in sales/revenue/volumes?

Target to reach INR 1,000 crores annual revenue by FY'28 or FY'29. Growth plan includes 20% contribution from hospital furniture and infra segments, 80% from packaging and containers. Volume and revenue growth expected to be balanced; focus on profitability rather than aggressive top-line growth. For FY'27, aiming for minimum 30% revenue growth (~INR 450 crores), driven by volume expansion and new capacities, with growth expected mainly in the second half. Monthly and spot pricing contracts in place for raw materials to manage cost fluctuations. Capacity expansions underway including the new I

Future growth expectations in earnings/operating earnings/profits/EPS?

Targeting a minimum 30% revenue growth for FY'27, aiming to reach INR1,000 crores by FY'28/FY'29. EBITDA margin guidance is a sustainable minimum of 10%, with aspirations to exceed that. Q4 FY26 EBITDA margin was 16.45%, considered partly due to one-offs like the war situation; sustainable margin expected around 10%. Net profit margin for FY26 improved to 4.46%, with EPS growth over 113% compared to previous year. Growth driven by volume expansion, value-added verticals like healthcare furniture (Furnastra) and infrastructure, and strategic IBC segment. Growth in hospital furniture and infrast

Current/ Expected Orderbook/ Pending Orders?

Mitsu Chem Plast Limited does not maintain a long-term order book due to the nature of the blow molding business, where order visibility typically lasts for about one month. The company's 30% growth guidance for FY'27 is based more on planning and historical customer data rather than firm, long-term order book visibility. They have a broad customer base, having added over 175 customers last year to improve margins and profitability. Growth is expected to be gradual, with higher revenue run rates anticipated in the second half of FY'27. The company is cautious and focuses on profitability rathe

IN US

Sale is live|00:00:00left today

Mitsu Chem Plast LtdQ1 FY26Industrial Products

Mitsu Chem Plast Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹151P/E: 9.6Market Cap: ₹151 CrSector: Industrial Products

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Target to reach INR 1,000 crores annual revenue by FY'28 or FY'29.
→Growth plan includes 20% contribution from hospital furniture and infra segments, 80% from packaging and containers.
→Volume and revenue growth expected to be balanced; focus on profitability rather than aggressive top-line growth.
→For FY'27, aiming for minimum 30% revenue growth (~INR 450 crores), driven by volume expansion and new capacities, with growth expected mainly in the second half.
→Monthly and spot pricing contracts in place for raw materials to manage cost fluctuations.
→Capacity expansions underway including the new IBC project and the fourth manufacturing unit.
→Volume expected to increase from around 21,000 tons in FY'26 to approximately 27,000 tons in FY'27 due to expansion efforts.
→Cautious and gradual scaling to maintain margins and avoid compromising profitability.

Margin guidance

Category 3

→Targeting a minimum 30% revenue growth for FY'27, aiming to reach INR1,000 crores by FY'28/FY'29.
→EBITDA margin guidance is a sustainable minimum of 10%, with aspirations to exceed that.
→Q4 FY26 EBITDA margin was 16.45%, considered partly due to one-offs like the war situation; sustainable margin expected around 10%.
→Net profit margin for FY26 improved to 4.46%, with EPS growth over 113% compared to previous year.
→Growth driven by volume expansion, value-added verticals like healthcare furniture (Furnastra) and infrastructure, and strategic IBC segment.
→Growth in hospital furniture and infrastructure expected to rise from 16% to 20% of revenue mix by FY28.
→Capex and capacity expansions underway, targeting operational efficiency and scaling exports.
→Earnings per share for Q4 FY26 at INR 5.68 and full year FY26 at INR 11.50, reflecting strong profitability improvement.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific details on any current or immediate fundraising through debt or equity were disclosed in the discussion.
→The company mentioned plans for capex related to expansion (e.g., Boisar and Tarapur projects, and IBC project) but indicated that announcements on the specifics, including financing, will be made in due course, particularly by Q2.
→Management emphasized phased capex and cautious scaling to protect margins and maintain ROCE but did not elaborate on the mode of funding.
→Overall, while growth and expansion plans imply potential future fundraising needs, there is no explicit mention of any ongoing or planned debt or equity raising as of the latest update.

Order book

→Mitsu Chem Plast Limited does not maintain a long-term order book due to the nature of the blow molding business, where order visibility typically lasts for about one month.
→The company's 30% growth guidance for FY'27 is based more on planning and historical customer data rather than firm, long-term order book visibility.
→They have a broad customer base, having added over 175 customers last year to improve margins and profitability.
→Growth is expected to be gradual, with higher revenue run rates anticipated in the second half of FY'27.
→The company is cautious and focuses on profitability rather than aggressively pursuing volume sales that could compromise margins.

Capex plans

Yes

→Mitsu Chem Plast Limited has ongoing and planned capital expenditure (capex) linked to capacity expansion, particularly at Boisar and Tarapur facilities.
→The company has recently started Unit 4 and is expanding packaging lines and IBC production capacity.
→Additional capex will be required to achieve the INR 1,000 crores revenue target by FY'28/FY'29.
→Specific capex amounts and detailed project updates are to be announced progressively, with a significant project (IBC) details expected by Q2.
→The company follows phased capex plans aligned with operational readiness and market demand.
→Emphasis on careful execution to sustain margins without undue sacrifice.
→Strategic investments include scaling verticals such as Furnastra (healthcare furniture) and IBC (Intermediate Bulk Containers), targeting better profitability and export growth.

How does Mitsu Chem Plast Ltd rank vs peers in Industrial Products?

Pro feature

1Mitsu Chem Plast Ltd

Rev 2Mar 3

See full Industrial Products sector rankings

Want more stocks like Mitsu Chem Plast Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio